Patents matching “anti-”

US 10513557

Anti-ASIC1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Dec 24, 2019 · Expires Dec 19, 2039

US 10513533

Tunicamycin related compounds with anti-bacterial activity

The United States of America, as represented by the Secretary of Agriculture · Granted Dec 24, 2019 · Expires Dec 19, 2039

US 10501538

Anti-LILRB antibodies and their use in detecting and treating cancer

The Board of Regents of the University of Texas System · Granted Dec 10, 2019 · Expires Dec 5, 2039

US 10494444

Anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Dec 3, 2019 · Expires Nov 28, 2039

US 10493149

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH · Granted Dec 3, 2019 · Expires Nov 28, 2039

US 10472425

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Nov 12, 2019 · Expires Nov 7, 2039

US 10466259

Synthetic antigen compositions for detecting anti-phosphatidylethanolamine antibodies

Northwestern University · Granted Nov 5, 2019 · Expires Oct 31, 2039

CA 3098014

CELLULES CAR-T ANTI-BCMA POUR DEPLETION DE CELLULES PLASMATIQUES

CRISPR THERAPEUTICS AG [CH] · Granted Oct 31, 2019 · Expires Oct 26, 2039

US 10457745

Anti-complement C1s antibodies

Bioverativ USA Inc. · Granted Oct 29, 2019 · Expires Oct 24, 2039

US 10456373

Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon

OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM” · Granted Oct 29, 2019 · Expires Oct 24, 2039

US 10450382

Anti-complement C1s antibodies

Bioverativ USA Inc. · Granted Oct 22, 2019 · Expires Oct 17, 2039

US 10450372

Anti-thyroglobulin T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 22, 2019 · Expires Oct 17, 2039

US 10444237

Anti-pancreatic cancer monoclonal antibody and use thereof

NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD. · Granted Oct 15, 2019 · Expires Oct 10, 2039

US 10441552

Anti-microbial composition comprising cannabinoids

AXIM BIOTECHNOLOGIES. INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

US 10442864

Anti-Tie2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

US 10442856

Methods of treating obesity with anti-ANGPTL8 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

US 10435473

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Oct 8, 2019 · Expires Oct 3, 2039

US 10428008

Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDs) and methods of treating inflammation related conditions

INSTITUT PASTEUR DE MONTEVIDEO · Granted Oct 1, 2019 · Expires Sep 26, 2039

US 10426797

Compositions and methods for treating cancer with anti-CD33 immunotherapy

United State of America, As Represented by the Secretary, Dept. of Health and Human Services · Granted Oct 1, 2019 · Expires Sep 26, 2039

CA 3094934

FORMULATIONS AQUEUSES STABLES D'ANTICORPS ANTI-TAU

ABBVIE DEUTSCHLAND [DE] · Granted Sep 26, 2019 · Expires Sep 21, 2039

US 10421805

Anti-hepatitis C antibodies and antigen binding fragments thereof

United Kingdom Research and Innovation · Granted Sep 24, 2019 · Expires Sep 19, 2039

US 10421945

Agents and methods to elicit anti-tumor immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 24, 2019 · Expires Sep 19, 2039

US 10421804

Anti-Zika virus antibodies and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Sep 24, 2019 · Expires Sep 19, 2039

US 10420851

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

Actinium Phamaceuticals, Inc. · Granted Sep 24, 2019 · Expires Sep 19, 2039